We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

481 hedge funds and large institutions have $8.05B invested in Teva Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 177 increasing their positions, 132 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more first-time investments, than exits

New positions opened: 72 | Existing positions closed: 33

46% more call options, than puts

Call options by funds: $371M | Put options by funds: $255M

34% more repeat investments, than reductions

Existing positions increased: 177 | Existing positions reduced: 132

31% more capital invested

Capital invested by funds: $6.16B → $8.05B (+$1.89B)

20% more funds holding in top 10

Funds holding in top 10: 20 → 24 (+4)

8% more funds holding

Funds holding: 447 → 481 (+34)

1.34% less ownership

Funds ownership: 52.26% → 50.92% (-1.3%)

Holders
481
Holders Change
+34
Holders Change %
+7.61%
% of All Funds
6.93%
Holding in Top 10
24
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+20%
% of All Funds
0.35%
New
72
Increased
177
Reduced
132
Closed
33
Calls
$371M
Puts
$255M
Net Calls
+$116M
Net Calls Change
+$125M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$233M
2
GCM
Glenview Capital Management
New York
+$74.3M
3
PC
PointState Capital
New York
+$64.3M
4
PCM
Parsifal Capital Management
Connecticut
+$63.6M
5
Neuberger Berman Group
Neuberger Berman Group
New York
+$50.5M

Top Sellers

1
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$359M
2
Morgan Stanley
Morgan Stanley
New York
-$139M
3
LIM
Lingotto Investment Management
United Kingdom
-$101M
4
Capital International Investors
Capital International Investors
California
-$85.6M
5
Citadel Advisors
Citadel Advisors
Florida
-$81.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$617M +$25.7M +2,039,540 +5%
IAM
2
Ion Asset Management
Israel
$544M -$22M -1,748,920 -4%
PF
3
Phoenix Financial
Israel
$488M +$2.5M +198,595 +0.6%
MIFH
4
Migdal Insurance & Financial Holdings
Israel
$421M +$11.8M +938,260 +3%
CI
5
Clal Insurance
Israel
$406M -$50.5M -4,009,765 -12%
MMH
6
Menora Mivtachim Holdings
Israel
$397M – – –
SPC
7
Slate Path Capital
New York
$380M +$8.38M +665,000 +3%
LIM
8
Lingotto Investment Management
United Kingdom
$373M -$101M -8,033,121 -23%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$300M +$233M +18,523,048 +680%
RCMNY
10
Rubric Capital Management (New York)
New York
$249M -$7.02M -557,013 -3%
State Street
11
State Street
Massachusetts
$229M -$1.8M -142,754 -0.9%
Millennium Management
12
Millennium Management
New York
$152M -$54.5M -4,322,067 -29%
A
13
AustralianSuper
Australia
$141M +$13.5M +1,073,000 +12%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$114M +$4.08M +323,737 +4%
Renaissance Technologies
15
Renaissance Technologies
New York
$109M +$28.5M +2,261,800 +42%
GCM
16
Glenview Capital Management
New York
$106M +$74.3M +5,896,651 +367%
SSM
17
Sound Shore Management
Connecticut
$106M -$18M -1,424,544 -16%
Alyeska Investment Group
18
Alyeska Investment Group
Illinois
$89.5M +$11.2M +886,499 +16%
EP
19
Eversept Partners
New York
$85M -$1.63M -129,185 -2%
Morgan Stanley
20
Morgan Stanley
New York
$76.6M -$139M -11,024,540 -67%
Citadel Advisors
21
Citadel Advisors
Florida
$72.1M -$81.9M -6,493,437 -56%
PC
22
PointState Capital
New York
$72M +$64.3M +5,104,969 New
PCM
23
Parsifal Capital Management
Connecticut
$71.2M +$63.6M +5,048,300 New
Holocene Advisors
24
Holocene Advisors
New York
$70M -$3.73M -295,739 -6%
MRCP
25
Maple Rock Capital Partners
Ontario, Canada
$61.6M +$22.3M +1,770,000 +68%
1
2 3 4 5

TEVA Hedge Fund Activity: Q1 2024 in Review

481 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2024, worth a combined $8.05B — up 31% from $6.16B a quarter earlier.

Buyers outnumbered sellers: 72 funds opened new TEVA positions and 33 closed out — a net gain of 39 holders — while 177 added to existing stakes and 132 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $233M. The largest seller was Harel Insurance Investments & Financial Services, cutting an estimated $359M.

  • 481 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2024, up from 447 in Q4 2023.
  • Funds reported $8.05B of Teva Pharmaceuticals stock for Q1 2024, up 31% quarter-over-quarter.
  • 72 funds opened new Teva Pharmaceuticals positions in Q1 2024 and 33 closed out, a net change of +39 holders.
  • The largest Teva Pharmaceuticals buyer in Q1 2024 was Fidelity Investments, an estimated $233M added.
  • The largest Teva Pharmaceuticals seller in Q1 2024 was Harel Insurance Investments & Financial Services, an estimated $359M sold.

Based on aggregated 13F filings for Q1 2024.